Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study to Investigate the Efficacy and Safety of Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Solid Tumor

NCT04215159 is registered in ClinicalTrials.gov with Jin-Hee Ahn as lead sponsor.

NCT NCT04215159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04215159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study to Investigate the Efficacy and Safety of Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Solid Tumor
Lead sponsor
Jin-Hee Ahn
Phase
Phase 2
Overall status
Unknown status
Start date
December 30, 2019
Completion date
December 30, 2019
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 gene amplification, her-2 protein overexpression